Angie Ballard

Angie Ballard has extensive experience in the healthcare industry, primarily focusing on market access and reimbursement. Currently, they hold the position of Senior Director Market Access at scPharmaceuticals. Previously, they worked at Iovance Biotherapeutics, Inc. as the Director of US Payor + Access Oncology Cell Therapy from 2020 to 2022. Prior to that, they were the Senior Director, Head of US Oncology Field Market Access at UroGen Pharma in 2020. From 2018 to 2020, they served as the Director of Oncology Market Access, Reimbursement & Policy at Stemline Therapeutics, Inc. Angie's experience also includes working as an Associate Director of Oncology Field Reimbursement at Algeta ASA (purchased by Bayer) from 2013 to 2018. Before that, they were an Immunotherapy Oncology Sales Specialist at Dendreon from 2011 to 2013. Angie started their career in the healthcare industry at Ortho Biotech as a Senior Sales Specialist in Nephrology from 2004 to 2006. Throughout their career, Angie has demonstrated expertise in reimbursement strategies, market access, and building strong relationships with key stakeholders in the healthcare field.

Angie Ballard is currently pursuing a Masters of Public Health degree from the University of North Carolina at Chapel Hill, with an expected graduation year in 2023. Prior to this, they obtained a Bachelor of Science (BS) degree in Biochemistry from North Carolina State University. Additionally, Angie has a certification as an Emergency Medical Technician, although the details of the institution and date of obtaining the certification are not provided.